BMS nets another Opdivo lung cancer win—but it still has to beat Merck's high bar

22nd October 2019 Uncategorised 0

It’s been a rocky road for Bristol-Myers Squibb’s immuno-oncology duo in previously untreated non-small cell lung cancer, but a new addition to the regimen might hold the ticket. Tuesday, the New Jersey drugmaker said its Opdivo-Yervoy duo—plus two cycles of chemo—had lengthened patients’ lives compared with placebo in a phase 3 study.

More: BMS nets another Opdivo lung cancer win—but it still has to beat Merck's high bar
Source: fierce